Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulse rhythm01:30

Pulse rhythm

717
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
717
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

699
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
699

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Safety Outcomes of Patients Admitted to Different Specialty Wards: The Prospective, Multi-center, Controlled SISIFO Study.

Journal of patient safety·2026
Same author

(<i>S</i>,<i>S</i>)-5-Chloro-3-((3,5-dimethylphenyl)sulfonyl)-<i>N</i>-(1-oxo-1-((1-(pyridin-4-yl)ethyl)amino)propan-2-yl)-1<i>H</i>-indole-2-carboxamide, a New Dishevelled 1 and P-Glycoprotein Dual Inhibitor as a Anticancer Agent.

Journal of medicinal chemistry·2026
Same author

ANMCO position paper E-health integration in cardiology clinical care framework.

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Correction to "Ferroptosis Induction by a New Pyrrole Derivative in Triple Negative Breast Cancer and Colorectal Cancer".

Journal of medicinal chemistry·2026
Same author

[ANMCO Position paper: e-Health management in cardiovascular care pathways].

Giornale italiano di cardiologia (2006)·2026
Same author

Ergonomics and Management of Floseal Kit in Five Surgical Specialties and Medico-legal Implications.

Reviews on recent clinical trials·2026
Same journal

Tailoring the CFIR to Medication Adherence Interventions: A Delphi and Living Lab Study.

Pharmacy (Basel, Switzerland)·2026
Same journal

Seasonal Influenza Vaccination Uptake, Illness and Economic Burden, and Vaccine Information Exposure Among Young Adults in the San Francisco Bay Area.

Pharmacy (Basel, Switzerland)·2026
Same journal

Impact of an Interdisciplinary Educational Intervention on Healthcare Provider Knowledge and Beliefs Regarding Opioid Harm Reduction in Older Adults: A Pre-Post Survey Study.

Pharmacy (Basel, Switzerland)·2026
Same journal

From Laboratory to Patient Access: A Scoping Review of the Multi-Dimensional Challenges in Drug Repurposing.

Pharmacy (Basel, Switzerland)·2026
Same journal

Kisspeptin as a Precision Biomarker in Personalized Pharmacy: Implications for Individualized Monitoring of Early Pregnancy Viability.

Pharmacy (Basel, Switzerland)·2026
Same journal

Enhancing Discretion and Consistency in Emergency Contraception Counselling: Implementation of a Digital Support Tool in Community Pharmacies.

Pharmacy (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: May 8, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K

AIHEMAF-P: An Innovative Healthcare Model for Atrial Fibrillation Patients.

Raffaele La Regina1, Pasquale Innelli2, Fulvio Glisenti3

  • 1Farmacia La Regina, 84030 San Rufo, Italy.

Pharmacy (Basel, Switzerland)
|December 27, 2024
PubMed
Summary
This summary is machine-generated.

A pilot study implemented a smart clinic model with pharmacists managing atrial fibrillation (AF) patients using telemedicine. This model improved adherence, detected drug interactions, and identified complications, demonstrating its value in patient care.

Keywords:
POCTatrial fibrillationcase managementclinical pathwaycommunity pharmacyhealth system transformationinterprofessional careinterprofessional cooperationpharmacy servicestelemedicine

More Related Videos

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.3K

Related Experiment Videos

Last Updated: May 8, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.2K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.3K

Area of Science:

  • Cardiology
  • Pharmacology
  • Health Services Research

Background:

  • Atrial fibrillation (AF) is a common arrhythmia leading to significant cardiovascular morbidity and mortality.
  • Current management of AF involves anticoagulant and antiarrhythmic drugs, requiring ongoing monitoring for safety and efficacy.
  • There is a need for improved follow-up models to ensure the appropriateness and safety of long-term pharmacological treatments in AF patients.

Purpose of the Study:

  • To implement and evaluate an innovative smart clinic model for nonvalvular atrial fibrillation (AF) management.
  • To assess the role of a community pharmacist as a case manager utilizing telemedicine and point-of-care testing (POCT).
  • To evaluate adherence, treatment appropriateness, complication detection, and the impact of this model on healthcare providers and patients.

Main Methods:

  • Pilot study involving 47 nonvalvular AF patients managed via a smart clinic model at a rural pharmacy.
  • Pharmacist acted as case manager, with patients using telemedicine and POCT for remote monitoring.
  • Data collected included adherence, drug-drug interactions, hemorrhagic/thromboembolic events, and clinician acceptance of pharmacist reports.

Main Results:

  • 93% compliance with planned checks; 11% of patients had inappropriate anticoagulant dosage at enrollment.
  • 98% adherence to anticoagulant therapy; 214 drug-drug interactions detected; 13% experienced major hemorrhagic events.
  • 109 pharmacist reports issued, with 84% accepted by referring clinicians; no embolic events observed.

Conclusions:

  • The smart clinic model, integrating community pharmacists into the care network, enhances patient adherence and disease control.
  • This model facilitates early diagnosis of complications and supports cost savings for the National Health Service.
  • Community pharmacy services are vital in improving individual care plan adherence and reducing morbidity in AF patients.